Biomedical subjects

Tachio Hikita

Publications and source records attributed to Tachio Hikita.

5 recordsLinked to original sources

PubMed2006

The "cross" signs in patients with multiple system atrophy: a quantitative study.

Patients with multiple system atrophy (MSA) may show the "cross" sign in the pontine base that has been considered as an expression of the degeneration of pontine neurons and transverse pontocerebellar fibers. However, correlations between pontine base atrophy and existence of "cross" sign have not been fully investigated. The authors studied 68 patients with MSA (47 MSA-C [predominantly cerebellar ataxia], 21 MSA-P [predominantly parkinsonism], mean [+/-SD ] 58.7 +/- 10.9 years). T1-weighted (T1W) sagittal and axial images and T2-weighted (T2W) axial images were obtained for all patients and controls. To measure the areas of pontine basis and cerebellar vermis, the authors used midsagittal T1W images and analyzed a bit map transformed on a computer. They classified atrophy in the pontine base into 3 grades. There is significant correlation between atrophies of pontine base and existence of the cross sign. All patients with a smaller area of pontine base 2 standard deviations below those of normal controls had the cross sign. This supports that existence of the cross sign depends only on the extent of pontine base atrophies.

Adult↗

PubMed2005

Sleep disturbances in Japanese patients with Parkinson's disease--comparing with patients in the UK.

Sleep disorders are common in the general population and occur more frequently with advancing age. However, patients with Parkinson's disease (PD) have been known to have various sleep disturbances beyond those to be expected from the effect of aging alone. We tried to quantify the various aspects of nocturnal sleep problems in PD using the PD sleep scale (PDSS). 64 patients with PD and 60 age- and sex-matched controls completed the PDSS. After neurological examinations, we assessed the degree of sleep disorder by the PDSS. We evaluated the severity of PD by the Hoehn and Yahr Scale and the unified PD rating scale (UPDRS). To compare the various aspects of nocturnal sleep problems in PD between in Japan and in the United Kingdom (UK), we referenced and compared our results with those by Chaudhui et al. The PDSS scores in PD group were significantly different from those in controls. Individual items of the scale showed good discriminatory power between PD and controls. Overall tendencies were the same in Japan and in the UK, but there were some different points, especially absence of refreshing quality of sleep in Japan. We believe that the PDSS provides an objective method for targeted therapeutic approaches for the treatment of disturbed sleep in PD even among countries with different cultures, such as Japan and the UK.

Adult↗

PubMed2005

Determination of transverse relaxation rate for estimating iron deposits in central nervous system.

To determine the amount of iron deposits in the basal ganglia, we examined 13 healthy volunteers with a 1.5 T MRI system using three transverse relaxation rates measured with two sequences. The transverse relaxation rates comprise the reversible contribution (R2') and irreversible contribution (R2) to a phase-reversal 180 degrees -pulse sequence. The transverse relaxation rates with the estimated iron indicated that both R2 and R2' had a robust relationship with brain iron level as determined from published post mortem data. This was the case only when the analyses are limited to the subcortical gray matter regions, however. R2' was affected by macroscopic magnetic field inhomogeneity arising from the skull bases, so that it was less robust for estimating the amount of iron deposits in the basal ganglia.

Adult↗

PubMed2005

[A hypnotic drug for sleep disturbances in patients with Parkinson's disease].

Patients with Parkinson's disease have been known to have sleep disturbances of various types. Zolpidem tartrate, an imidazopyrimidine short-acting hypnotic drug used treat insominia and several patients with PD have described a significant improvement of parkinsonian symptoms after administration of zolpidem tartrate. We tried to evaluate effect of zolpidem tartrate for sleep disturbances in patients with PD by a Japanese version of Chaudhuri's Parkinson's disease Sleep Scale (PDSS) and Unified Parkinson's disease rating Scale (UPDRS) motor scale. Twelve patients with PD (mean age 67.4 years old, range 40-77 years old) were evaluated by PDSS and UPDRS before and two weeks after prescribed zolpidem tartrate 5 mg per day. Patients showed improvement in items relating overall sleep disturbances, sleep refreshment and morning stiffness. Disabilities remained unchanged before and two weeks after prescribing zolipdem tartrate. Zolpidem tartrate may be useful for sleep disturbances in patients with PD and for improving their quality of daily livings.

Adult↗

PubMed2004

A pitfall in MRI.

Explore the source record for details and available documents.

False Negative Reactions↗